RxDoctor Payments Data

Wajahat Hussain, DO

Pulmonary Disease · Elmhurst, ILNPI 1730318858

Payments from drug & device makers

$12,684in general payments, 2019–2025

Across 155 payments — averaging $81.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$9K
  • GSK$2K
  • Boehringer Ingelheim$705
  • AstraZeneca$388
  • Johnson & Johnson$325
  • Sanofi$135
  • plus $365 from 7 others

What the payments were for

  • Travel & lodging$1,52912%
  • Food & beverage$3,65529%
  • Education$7,50059%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,684 in reported general payments places this provider in the 75th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$314,127
Medicare patients
895
Services billed
3,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter286$247,504
Breo ElliptaFluticasone/Vilanterol134$75,218
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr76$36,530
EliquisApixaban27$18,450
Spiriva HandihalerTiotropium Bromide12$11,865
SymbicortBudesonide/Formoterol Fumarate27$10,251
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$6,134
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$4,324
Albuterol Sulfate HfaAlbuterol Sulfate98$3,540
Wixela InhubFluticasone Propion/Salmeterol15$2,985
Ventolin HfaAlbuterol Sulfate17$1,131
Montelukast Sodium34$433
Bupropion Hcl SrBupropion Hcl14$246
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$241
Ipratropium Bromide17$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,568$359,253496 claims
AstraZenecaSymbicort$388$10,25127 claims
Boehringer IngelheimStiolto Respimat$705$6,13411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →